New Retina Radio:

New Retina Radio Meeting Coverage

New Retina Radio Meeting Coverage

11.30.21

AAO 2021 Late Breakers: DAVIO and NORSE-2

 Is a technology that inhibits tyrosine kinase and shows activity against all isoforms of VEGF and placental growth factor the future of wet AMD therapy? Data from the DAVIO study, which were shared at the 2021 AAO Annual meeting late-breakers session, could be of interest. David Boyer, MD, discussed the drug design of EYP-1901 (EyePoint Pharmaceuticals) and summarized the findings of the phase 1 DAVIO study, which examined the drug’s use in wet AMD patients. NRR also invited Firas Rahhal, MD, to review the safety and efficacy findings of the phase 3 NORSE-2 trial, which explored use of an ocular formation of bevacizumab (bevacizumab-vikg, Outlook Therapeutics) in patients with wet AMD.  This editorially independent podcast is supported with advertising.

Other Podcast Episodes

08.21.25

ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders

John Kitchens, MD; Krishna Mukkamala, MD

06.12.25

Duke AVS Clips: PVR, DR, Imaging, and MTM

Jason Hsu, MD; Majda Hadziahmetovic, MD; Aleksandra Rachitskaya, MD; Gavin Tan, MD, PhD, FRCSed

06.09.25

Duke AVS Clips: Pediatrics, Anesthesia Trends, and AI

Lejla Vajzovic, MD; Jason Fan, MD; Glen J. Jaffe, MD

06.05.25

Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs

Avni P. Finn, MD, MBA; Lejla Vajzovic, MD, MBA; David Zacks, MD, PhD; Dilraj S. Grewal, MD; Xi Chen, MD, PhD; Yuxi Zheng, MD; Durga Borkar, MD; and Yannek I. Leiderman, MD, PhD

05.29.25

ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data

Marion Munk, MD, PhD; and Diana Do, MD

05.22.25

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

David Miller, MD; and Robert Wang, MD

11.07.24

AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD

Jeremiah Brown, MD, MS; and Eric Schneider, MD

Show More